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Radiotherapy is a keystone in the treatment of prostate 
cancer (PC), oesophageal cancer (EC) and head 
and neck cancer (HNC). In PC, LBH589 degrades 
androgen receptors, a key regulator for cancer cell 
survival and proliferation. In squamous cell cancer, 
LBH589 is synergistic with radiation in preclinical 
models. Generally, there is a strong rationale to use 
pan-histone deacytelase inhibitor (HDACi) in HNC 
and gastrointestinal cancer. A phase I trial designed 
to assess the feasibility of combined administration 
of different oral LBH589 dosages in combination 
with ionizing irradiation in a selection of patients with 
PC, HNC and EC is currently starting at CHU-Liège. 
This will allow the optimal dose-establishment for 
further studies. 
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